SCHEMBL5219358

SCHEMBL5219358

CC(C)(C)C(=O)Oc1ccc(-n2cc(-c3ccc4ccccc4n3)cn2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.49
NPC1 O15118 5/20 0.49
RAB9A P51151 5/20 0.49
SMN1; SMN2 Q16637 5/20 0.49
ALDH1A1 P00352 4/20 0.49
MAPT P10636 4/20 0.49
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
HPGD P15428 2/20 0.49
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
MIF P14174 1/20 0.41
MAPKAPK2 P49137 1/20 0.39
ELANE P08246 5/20 0.39
AR P10275 1/20 0.39
GRM4 Q14833 3/20 0.38
PDE10A Q9Y233 1/20 0.38
GRM2 Q14416 1/20 0.38
XBP1 P17861 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5216714 0.87 MAPT (0.50) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL5216162 0.85 GRM4 (0.53) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL5217536 0.84 MIF (0.47) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3930712 0.81 GRM5 (0.46) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL5217390 0.79 NPC1 (0.42) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3923977 0.76 PDE10A (0.41) MAPKAPK2ELANEGRM4PDE10A
SCHEMBL8357392 0.73 MKNK1 (0.46) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL5217060 0.73 NPC1 (0.41) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL5215574 0.72 GRM4 (0.56) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL5256274 0.72 GRM5 (0.40) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
EP-1458383-A4 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-05-25 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
EP-1458383-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C KDM4E 2688/4885NPC1 4205/4885RAB9A 1352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.